Three separate supply channels reach men in this market and they carry different legal weight. Approved products move through a licensed pharmacy under a prescription. Compounded preparations come from a 503A pharmacy or a 503B outsourcing facility and are not FDA-approved. Research chemicals sit outside the drug supply chain altogether, with no prescriber, no pharmacy record, and no recall route.
Testosterone carries a layer the others do not
Testosterone is a Schedule III controlled substance in the United States. That single fact shapes the entire men’s hormone channel. Prescriptions cannot be refilled indefinitely, dispensing records are auditable, and the prescriber must hold both a state medical license and a Drug Enforcement Administration registration. A service that will ship testosterone after a form with no identity verification and no clinician contact is describing a workflow that does not match how controlled substances are dispensed.
The clinical bar is separate from the legal one. FDA states that approved testosterone products are indicated for men whose low levels are tied to an associated medical condition, such as testicular failure or a hypothalamic-pituitary disorder. After reviewing the TRAVERSE cardiovascular trial and other evidence, FDA requested prescribing information updates in June 2026 that removed the age-related hypogonadism limitation of use and revised the prostate safety language. Professional guidance still asks for consistent symptoms plus low morning fasting total testosterone confirmed on two separate occasions before treatment begins.
Two sections of compounding law, one shared limitation
A 503A pharmacy prepares a medication for a named patient against a prescription and answers primarily to its state board. A 503B outsourcing facility registers with FDA, produces in batches, follows current good manufacturing practice, and is subject to FDA inspection. Neither route yields an FDA-approved drug. Compounded preparations are not reviewed for safety, effectiveness or quality before a patient receives them, which is why the identity of the preparing facility carries the weight the approval would otherwise carry.
FDA has also reviewed many of the peptides marketed to men as bulk substances for compounding. Ipamorelin acetate, GHRP-2 for injectable and nasal routes, GHRP-6 and ibutamoren mesylate sit in category 2, the group flagged as presenting significant safety risks. BPC-157, CJC-1295, the thymosin beta-4 fragment sold as TB-500, MOTS-C, AOD-9604 and pegylated mechano growth factor appear on the separate list of substances nominated and then withdrawn. The stated concerns include immunogenicity by certain routes and difficulty characterizing peptide-related impurities.
The three channels compared
| Channel | Regulatory status | Who is accountable if something goes wrong |
|---|---|---|
| Approved product, retail or mail pharmacy | FDA-approved; testosterone additionally controlled at Schedule III | Manufacturer, dispensing pharmacist, prescriber, with a recall pathway and adverse event reporting |
| 503A compounding pharmacy | Not FDA-approved; patient-specific prescription required | State board of pharmacy, the named pharmacist, and the prescriber |
| 503B outsourcing facility | Not FDA-approved; registered with FDA and inspected | FDA inspection record, good manufacturing practice requirements, batch documentation |
| Research-chemical vendor | Unapproved and not dispensed as a medicine | Nobody. No prescription, no pharmacist, no lot traceability, no recall route |
Verifying the pharmacy takes a few minutes
Every state board of pharmacy publishes a license lookup, and most states require a nonresident license for a pharmacy shipping in from elsewhere. A service willing to name its pharmacy can be checked in both states, along with disciplinary history. Large compounding operations serving this market, including Empower Pharmacy, Hallandale Pharmacy and Tailor Made Compounding, can be looked up the same way.
The refusal is the signal. Inspection history and outsourcing facility registration cannot be checked for a facility that stays unnamed. The direct question worth putting to the provider behind it is which pharmacy prepares the order and under which section of the compounding law it operates, because the answer determines which regulator is watching and what documentation exists.
What the prescriber should have done first
For a man presenting with low drive, fatigue or a body composition complaint, an adequate evaluation looks past the requested product. Obesity lowers measured testosterone through recognized mechanisms and weight loss raises it. Obstructive sleep apnea is associated with lower total testosterone in meta-analysis. A week of restricted sleep lowered daytime testosterone in young healthy men. Erectile dysfunction tracks with cardiometabolic risk closely enough to be worth investigating in its own right.
An analysis of young men evaluated for erectile dysfunction found that direct-to-consumer prescription platforms missed pathology a standard office evaluation identified. Intake design is therefore a clinical variable, not a convenience feature.
What a legitimate shipment looks like
A compounded sterile preparation should arrive with a patient-specific label carrying the patient name, the preparing pharmacy’s name and contact details, the contents and strength, a lot or reference number, and a beyond-use date. Sterile preparations expire sooner than manufactured drugs, which is why transit time and cold packs matter. A vial with a generic sticker, no pharmacy identified, or wording such as for research use only did not come through a prescription pathway.
The analytical record for the unregulated channel is poor. Impurity profiling of falsified polypeptide drugs found wide variation in active ingredient content along with contaminants and residual solvents, and a study of internet-sourced somatropin found products of unreliable quality. Preparation error is a separate risk: a pharmacovigilance analysis reported higher odds of preparation errors and contamination for compounded versus manufactured products in one drug class, and a poison control case series documented dosing errors traced to unclear labeling and unit confusion.
The same test separates the larger named platforms. Hims and Hers, Ro, and Henry Meds each disclose the pharmacies they work with to varying degrees, and a provider such as HealthRX describes how its peptide therapy is sourced and which section of the compounding law applies. A service that answers those questions in writing can be checked against a state board register, while one that will not name the pharmacy is asking for trust it has not earned.
Frequently asked questions
Can a legitimate service prescribe testosterone after an online visit?
Yes, within limits. The clinician must be licensed in the patient’s state and registered to prescribe controlled substances, and the encounter has to establish a genuine treatment relationship. Refills are restricted by Schedule III rules, so a service promising an indefinite automatic supply without follow-up is describing something the law does not permit.
Is a 503B facility better than a 503A pharmacy?
Different rather than better. Outsourcing facilities register with FDA, follow good manufacturing practice and get inspected, which suits batch production. A 503A pharmacy compounds against an individual prescription under state board oversight. Neither produces an approved product, and both leave a verifiable public record.
What should be on the vial label?
The patient’s name, the preparing pharmacy and its contact details, the drug and strength, a lot or reference number, and a beyond-use date. Missing any of those means the shipment cannot be traced back if a problem appears, and beyond-use dating is the item most often absent from gray-market vials.
Does buying a peptide labeled for research use avoid the prescription requirement?
It avoids the pharmacy, not the risk. That label places the product outside the dispensing system, so there is no pharmacist, no lot record, no recall mechanism and no clinician attached. Published analyses of internet-sourced peptides repeatedly found contents that did not match the labeling.
